Antibody composition, and applications thereof in Lymphoplasmacytic Lymphoma (LPL) minimal residual detection (MRD)

Abstract

The invention provides an antibody composition, and applications thereof in Lymphoplasmacytic Lymphoma minimal residual detection. Based on a plurality of years of clinical practice and research, twotubes eight colors 16 antibody compositions are obtained via screening, and high efficiency high sensitivity distinguishing identifying of abnormal cell population is realized; on the above base, FITC, PE, Percp5.5, Pe-cy7, APC, AF750, BV421, and V500 fluorescent labels are selected preferably, and results of eight kinds of antibodies are obtained in detection of one flow tube in an eight color flow cytometry single tube. In addition, a corresponding analysis method of the detection results is designed based on 45 / SSC combination, so that it is possible to determine whether plasmocyte, B lymphocyte clonality, and abnormal lymphoplasmacytoid are detected. The antibody composition can be directly used for MRD detection of LPL, and can also be used for preparation of related kits.

Description

technical field [0001] The invention relates to the technical field of biological experiments, in particular to an antibody composition and its application in the detection of minimal residues of lymphoplasmacytic lymphoma. Background technique [0002] Lymphoplasmacytic lymphoma (LPL) is a neoplasm composed of abnormal small B lymphocytes, abnormal plasmacytoid lymphocytes, and abnormal plasma cells, usually involving the bone marrow, lymph nodes, and spleen. Minimal remnant leukemia (MRD) refers to the status of a small amount of leukemia cells remaining in the body after leukemia is completely remitted by induction chemotherapy or after bone marrow transplantation. At this time, it is difficult to detect the existence of leukemia cells by general morphological methods, but in fact, leukemia cells still exist in the patient's bone marrow, and these remaining cells become the source of leukemia recurrence. [0003] In the process of diagnosis and treatment of blood disease...

AI Technical Summary

Problems solved by technology

[0004] The present invention aims at the technical defects of the prior art, and provides an antibody composition and its application in the detection of minimal residual lymphoplasmacytic lymphoma, so as to solve the lack of a method for detecting lymphoplasmacytic lymphoma in the prior art. Technical issues with the minimal residue approach

[0005] Another technical problem to be solved by the present invention is the lack of an antibody composition for flow cytometry detection of lymphoplasmacytic lymphoma microresidues and a clinical analysis method surrounding the detection results in the prior art